Comparative Pharmacology
Head-to-head clinical analysis: MECLOMEN versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOMEN versus NAPROXEN SODIUM.
MECLOMEN vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID